Clinical trials: Moderate to Severe Psoriasis
Chronic Plaque Psoriasis
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
- Trial name
- NCT02969018
- Testing
- PF-06700841
- Where
- 44 sites in United States, Canada and 1 more
- Volunteers
- 212 people
- Sponsor
- Pfizer
Psoriasis
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.
- Trial name
- NCT01543204
- Testing
- Etanercept
- Where
- 47 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Amgen
Plaque Psoriasis
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06176768
- Testing
- LY3972406
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- SUMMIT (NCT05357755)
- Testing
- JNJ-77242113
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.
- Trial name
- UNCOVER-A (NCT01777191)
- Testing
- Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Psoriasis
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206660
- Testing
- Desoximetasone Spray 0.25%
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE VIVID (NCT03370133)
- Testing
- Bimekizumab, Ustekinumab
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 567 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05600036
- Testing
- ESK-001
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 228 people
- Sponsor
- Alumis Inc
Psoriasis Chronic
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe…
- Trial name
- QUALITY (NCT01084668)
- Where
- 9 sites in Austria
- Volunteers
- 46 people
- Sponsor
- Abbott
Psoriasis
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic…
- Trial name
- NCT02325219
- Testing
- CNTO 1959 50 mg, CTNO 1959 100 mg
- Where
- 27 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Janssen Pharmaceutical K.K.
Chronic Plaque Psoriasis
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.
- Trial name
- NCT00245765
- Testing
- Certolizumab Pegol
- Where
- 15 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- UCB Pharma
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Moderate to Severe Palmar Plantar Psoriasis
Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
The purpose of this study is to determine the short and long term safety and effectiveness of ustekinumab in subjects with moderate to severe chronic palmar plantar psoriasis.
- Trial name
- PPP (NCT01090063)
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Tufts Medical Center
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Psoriasis, Plaque Psoriasis
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
- Trial name
- CIMPASI-1 (NCT02326298)
- Testing
- Certolizumab Pegol
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 234 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriatic Arthritis
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA.
- Trial name
- SPEED (NCT03739853)
- Testing
- Methotrexate, Sulfasalazine, Leflunomide
- Where
- United Kingdom
- Volunteers
- 192 people
- Sponsor
- University of Oxford
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Moderate to Severe Plaque Psoriasis
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE CONNECTED (NCT04718896)
- Testing
- bimekizumab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
The purpose of this research study is to see how well the medication Alefacept (Amevive®) works for continuous treatment of chronic plaque psoriasis.
- Trial name
- NCT00655564
- Testing
- Alefacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University